COVID-19: Melatonin as a potential adjuvant treatment

Life Sciences, Journal Year: 2020, Volume and Issue: 250, P. 117583 - 117583

Published: March 23, 2020

Language: Английский

---

Significance of Melatonin in the Regulation of Circadian Rhythms and Disease Management

Molecular Neurobiology, Journal Year: 2024, Volume and Issue: 61(8), P. 5541 - 5571

Published: Jan. 11, 2024

Language: Английский

---

Can Melatonin Be a Potential “Silver Bullet” in Treating COVID-19 Patients?

Diseases, Journal Year: 2020, Volume and Issue: 8(4), P. 44 - 44

Published: Nov. 26, 2020

The therapeutic potential of melatonin as a chronobiotic cytoprotective agent to counteract the consequences COVID-19 infections has been advocated. Because its wide-ranging effects an antioxidant, anti-inflammatory, and immunomodulatory compound, could be unique in impairing SARS-CoV-2 infection. Moreover, indirect evidence points out possible antiviral action by interfering with SARS-CoV-2/angiotensin-converting enzyme 2 association. Melatonin is also effective reverse circadian disruption social isolation control delirium severely affected patients. As cytoprotector, serves combat several comorbidities such diabetes, metabolic syndrome, ischemic non-ischemic cardiovascular diseases, which aggravate disease. In view on occurrence neurological sequels COVID-19-infected patients, another putative application emerges based neuroprotective properties. Since means cognitive decay minimal impairment, significance for infection should considered. Finally, yet importantly, exogenous can adjuvant capable augmenting efficacy anti-SARS-CoV-2 vaccines. We discuss this review experimental suggesting that “silver bullet” COVID 19 pandemic.

Language: Английский

---

The Effects of Melatonin Supplementation on Sleep Quality and Assessment of the Serum Melatonin in ICU Patients: A Randomized Controlled Trial

Critical Care Medicine, Journal Year: 2020, Volume and Issue: 48(12), P. e1286 - e1293

Published: Oct. 13, 2020

Objectives: To evaluate whether the use of exogenous melatonin affects sleep, reduces prevalence delirium, and decreases need for analgosedation to assess serum indices correlate with administration in critically ill patients. Design: Double-blind, randomized, placebo-controlled study. Setting: Multicenter ICUs two tertiary hospitals. Patients: A total 203 adult patients who were admitted ICU administered analgesics and/or sedatives. Interventions: Oral (10 mg) or placebo up seven consecutive nights. Measurements Main Results: The number observed sleeping hours at night was assessed by bedside nurse. Sleep quality evaluated using Richards Campbell Questionnaire (RCSQ). pain, anxiety, adverse reactions, duration mechanical ventilation, length hospital stays, doses sedative analgesic drugs recorded. sedatives daily. Melatonin levels determined enzyme-linked immunosorbent assay. Based on RCSQ results, sleep be better group than that a mean ( sd ) 69.7 (21.2) 60.7 (26.3), respectively p = 0.029). About 45.8% 34.4% participants groups had very good (risk ratio, 1.33; 95% CI, 0.94–1.89), whereas 3.1% 14.6% poor 0.21; 0.06–0.71), respectively. No significant difference regarding days free sedatives, occurrence anxiety. peak 2 am 150 pg/mL (range, 125–2,125 pg/mL) 32.5 18.5–35 < 0.001). Conclusions: associated quality, which suggests its possible role routine care future.

Language: Английский

---

Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed

Nutrients, Journal Year: 2020, Volume and Issue: 12(9), P. 2561 - 2561

Published: Aug. 24, 2020

The recent pandemic of COVID-19 has already infected millions individuals and resulted in the death hundreds thousands worldwide. Based on clinical features, pathology, pathogenesis respiratory disorders induced by this other highly homogenous coronaviruses, evidence suggests that excessive inflammation, oxidation, an exaggerated immune response contribute to pathology; these are caused severe acute syndrome coronavirus 2 (SARS-CoV-2). This leads a cytokine storm subsequent progression triggering lung injury (ALI)/acute distress (ARDS), often death. We others have reported melatonin be anti-inflammatory anti-oxidative molecule with high safety profile. It is effective critical care patients reducing their vascular permeability anxiety, inducing sedation, improving quality sleep. As shows no harmful adverse effects humans, it imperative introduce indoleamine into trials where might beneficial for better outcomes as adjuvant treatment COVID-19-infected patients. Herein, we strongly encourage health professionals test potential targeting pandemic. urgent, since there reliable devastating disease.

Language: Английский

---

International Expert Opinions and Recommendations on the Use of Melatonin in the Treatment of Insomnia and Circadian Sleep Disturbances in Adult Neuropsychiatric Disorders

Frontiers in Psychiatry, Journal Year: 2021, Volume and Issue: 12

Published: June 10, 2021

Introduction: Insomnia and circadian rhythm disorders, such as the delayed sleep phase syndrome, are frequent in psychiatric disorders their evaluation management early stages should be a priority. The aim of this paper was to express recommendations on use exogenous melatonin, which exhibits both chronobiotic sleep-promoting actions, for treatment these disturbances disorders. Methods: To aim, we conducted systematic review according PRISMA melatonin insomnia neuropsychiatry. We expressed clinical practice each disorder using RAND/UCLA appropriateness method. Results: selected 41 studies, included mood schizophrenia, substance attention deficit hyperactivity autism spectrum neurocognitive delirium; no studies were found anxiety eating Conclusion: administration prolonged release at 2–10 mg, 1–2 h before bedtime, might used symptoms or comorbid adults with during sedative-hypnotics discontinuation. Immediate &lt;1 mg useful neuropsychiatric

Language: Английский

---

Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(16), P. 8623 - 8623

Published: Aug. 11, 2021

Melatonin is registered to treat circadian rhythm sleep–wake disorders and insomnia in patients aged 55 years over. The essential role of the sleep deterioration quality during COVID-19 confinement lack an adverse effect melatonin on respiratory drive indicate that has potential be a recommended treatment for disturbances related COVID-19. This review article describes effects additional its sleep-related effects, which make this drug attractive therapeutic option treating with preclinical data suggest may inhibit progression. It lower risk entrance SARS-CoV-2 virus into cells, reduce uncontrolled hyper-inflammation activation immune limit damage tissues multiorgan failure due action free radicals, ventilator-induced lung injury disability resulting from fibrotic changes within lungs. also increase efficacy vaccination. high safety profile anti-SARS-CoV-2 molecule preferable patients. However, randomized clinical trials are needed verify usefulness

Language: Английский

---

Efficacy of melatonin in the treatment of patients with COVID‐19: A systematic review and meta‐analysis of randomized controlled trials

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 94(5), P. 2102 - 2107

Published: Jan. 15, 2022

Abstract This study investigated the effect of melatonin on clinical outcomes in patients with coronavirus disease 2019 (COVID‐19). We searched PubMed, Web Science, Cochrane Library, Ovid MEDLINE, and Clinicaltrials.gov for randomized controlled trials (RCTs) published before September 11, 2021. Only RCTs that compared efficacy a placebo treatment COVID‐19 were included. The primary outcome measure was recovery rate. included three this meta‐analysis. Melatonin 3 mg times daily administered one RCT, or 6 bedtime other two trials. Treatment duration 14 days 7 trial. rates 94.2% (81/86) 82.4% (70/85) control groups, respectively. Overall, receiving had higher rate than did controls (odds ratio [OR]: 3.67; 95% CI: 1.21−11.12; I 2 = 0%, p 0.02). risk intensive care unit admission numerically lower group (8.3% [6/72] vs. 17.6% [12/68], OR: 0.45; 0.16−1.25; 0.13), mortality (1.4% [1/72] 4.4% [3/68], 0.32; 0.03−3.18; 0.33). In conclusion, may help improve COVID‐19.

Language: Английский

---

Sleep and circadian rhythm disturbances in intensive care unit (ICU)-acquired delirium: a case–control study

Journal of International Medical Research, Journal Year: 2021, Volume and Issue: 49(3)

Published: March 1, 2021

Objective The relationships among sleep, circadian rhythm, and intensive care unit (ICU)-acquired delirium are complex remain unclear. This study aimed to examine the pathophysiological mechanisms of sleep rhythm disturbances in patients with ICU-acquired delirium. Methods included critical adult aged 18 75 years who were treated ICU. Twenty-four-hour polysomnography was performed serum melatonin cortisol levels measured six times during polysomnography. Receiver operating characteristic curves binomial logistic regression used evaluate potential melatonin, as indicators Results Patients (n = 24) showed less rapid eye movement (REM) compared without 24, controls). Melatonin lower higher group than control group. REM significantly associated optimal cutoff values mean that predicted ≤1.05%, ≤422.09 pg/mL, ≥212.14 ng/mL, respectively. Conclusions risk Improved readjustment rhythmicity may be therapeutic targets

Language: Английский

---

Sleep-Based Interventions in Alzheimer’s Disease: Promising Approaches from Prevention to Treatment along the Disease Trajectory

Pharmaceuticals, Journal Year: 2021, Volume and Issue: 14(4), P. 383 - 383

Published: April 19, 2021

The multifactorial nature of Alzheimer's disease (AD) has led scientific researchers to focus on the modifiable and treatable risk factors AD. Sleep fits into this context, given bidirectional relationship with AD confirmed by several studies over last years. disorders appear at an early stage continue throughout entire course pathology. Specifically, sleep abnormalities, such as more fragmented sleep, increase in time awakenings, worsening quality primary raise severity progression Intervening therefore, means acting both prevention strategies pre-clinical phase treatments during disease. This review explores disturbances different stages AD, starting from stage. Particular attention is empirical evidence investigating obstructive apnea (OSA) disorder mechanisms overlapping sharing Next, we discuss sleep-based intervention healthy elderly population, mild cognitive impairment (MCI) patients. We mention interventions related behavioral strategies, combination therapies, bright light therapy, leaving extensive space for new raising continuous positive air pressure (CPAP) treatment effectiveness. Finally, clarify role NREM across trajectory consider most recent based promising results enhancement, which use innovative experimental designs techniques.

Language: Английский

---